EPIDERMOLYSIS BULLOSA, DYSTROPHIC
Clinical trials for EPIDERMOLYSIS BULLOSA, DYSTROPHIC explained in plain language.
Never miss a new study
Get alerted when new EPIDERMOLYSIS BULLOSA, DYSTROPHIC trials appear
Sign up with your email to follow new studies for EPIDERMOLYSIS BULLOSA, DYSTROPHIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New gel could help heal painful skin wounds in rare disease
Disease control Recruiting nowThis study tests a gel called Oleogel-S10 on skin wounds from two types of epidermolysis bullosa (EB), a rare genetic condition that makes skin very fragile. About 6 Japanese children and adults will apply the gel to their wounds at dressing changes for 45 days, with the option t…
Matched conditions: EPIDERMOLYSIS BULLOSA, DYSTROPHIC
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated May 17, 2026 09:26 UTC
-
Does a common EB gel raise or lower cancer risk? 5-year study aims to find out.
Knowledge-focused Recruiting nowThis study follows 580 people with dystrophic or junctional epidermolysis bullosa (EB) for up to 5 years. Researchers will compare those who use Filsuvez gel with those who don't, to see if the gel affects the chance of developing skin cancer. The goal is to gather safety data, n…
Matched conditions: EPIDERMOLYSIS BULLOSA, DYSTROPHIC
Sponsor: Amryt Pharma • Aim: Knowledge-focused
Last updated May 11, 2026 20:50 UTC